Lonza reported its business performance was in line with expectations in the first quarter of 2012 and that its custom manufacturing business has continued pipeline development and signed new contracts ranging from pre-clinical to commercial products. The company also reported that capacity utilisation in both chemical and biological manufacturing was 75%.
Lonza
Tuesday 8 May 2012
Lonza's Q1 in line with expectations
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment